Managing Side Effects of Tadalafil in Female Populations

The linear trend test and the log-rank test were performed on change in 6MWD and TCW by age. For tadalafil-treated patients, a significant difference in change in 6MWD by sex (mean: 48.6 m for males vs.

Why Choose Tadalafil & Oxytocin Therapy?

A backward model selection was performed with 0.05 as the significance level for staying in the model to assess any covariate correlation. This model selection resulted in elimination of the variables background therapy with bosentan (P = 0.8854), race (P = 0.1935), and sex (P = 0.0647). P = 0.01 for the difference between male and female change cheap tadalafil in 6MWD. P = 0.49 for the difference between male and female change in TCW. Overall, tadalafil treatment demonstrated a beneficial effect on TCW for patients who experienced clinical worsening compared with placebo in both male and female patients (Table 3).

Other Medical Problems

Female patients randomized to receive tadalafil were found to have a shorter mean (SD) TCW compared with male patients randomized to receive tadalafil (61 [29] vs. 79 [36] days). A log-rank test did not show a consistent effect of sex on TCW for tadalafil-treated patients (P = 0.49). This difference in TCW between the sexes was found to be not statistically significant in the multivariate analysis (P = 0.41). To assess the impact of menopausal status on treatment response, female subjects were subdivided by age as a surrogate for menopausal status (Table 4).

Cite this article

Tadalafil treatment demonstrated a consistent beneficial effect on change in 6MWD from baseline compared with placebo in these subgroups. 34.7 m for females; P = 0.01) was found, but it was not significant in multivariate analysis (P = 0.08). There was a trend toward a female age-dependent effect in change in 6MWD; the premenopausal group showed the greatest improvement. A significant sex- or age-dependent effect on TCW was not present. In conclusion, this retrospective analysis of the PHIRST trial suggests that men and premenopausal women may experience greater functional improvement when treated with tadalafil than older women, but there was no consistent sex or menopausal effect on TCW. Keywords: pulmonary arterial hypertension, sex differences, tadalafil, 6-minute walk distance, menopause Pulmonary arterial hypertension (PAH) is a group of disorders that are characterized by elevated pulmonary arterial resistance, leading to eventual right heart failure.1,2 PAH is a female-predominate disease; according to the REVEAL (Registry to Evaluate Early and Long-Term PAH Disease Management) Registry, group 1 PAH is four times more likely in female patients than in male patients.3-6 While the exact cause of the observed female predominance is unknown, it may potentially relate to a disruption in the protective effect of estrogen on the pulmonary vasculature and myocardium.7-11 A recent study examining patient factors as a predictor of treatment response with tadalafil found male sex to be predictive of improved change in 6-minute walk distance (6MWD).12 Despite this, there is a paucity of literature investigating the effect of menopause on response to PAH treatment. Providing more tailored therapy to patients may allow for more cost-conscious, targeted, and safer treatment for patients with PAH.

Product	Dosage	Quantity + Bonus	Price
Cialis Generic	20mg	180 + 10 Pills	254.09€ 241.99€	Buy
Cialis Generic	20mg	10 Pills	31.49€ 29.99€	Buy
Cialis Generic	2.5mg	270 + 10 Pills	199.64€ 190.13€	Buy
Cialis Generic	40mg	20 Pills	59.47€ 56.64€	Buy
Cialis Generic	5mg	30 + 4 Pills	53.56€ 51.01€	Buy
Tadalista Super Active	20mg	90 + 10 Pills	314.14€ 299.18€	Buy
Cialis Generic	60mg	20 Pills	65.61€ 62.49€	Buy
Tadalista Super Active	20mg	20 + 4 Pills	92.35€ 87.95€	Buy
Cialis Generic	2.5mg	20 Pills	40.73€ 38.79€	Buy
Cialis Generic	2.5mg	30 + 4 Pills	51.95€ 49.48€	Buy

Two prior sex-specific treatment response studies found opposing results for response to tadalafil and endothelin receptor antagonists (ERAs). ERAs have demonstrated a more robust change in 6MWD in female patients, while tadalafil has demonstrated a significant increase in 6MWD in male patients.12,13 The etiology of this sex difference between the treatment agents is unknown and could possibly involve differences in nitric oxide (NO) and endothelin signaling between the sexes.14,15 Multiple animal studies have demonstrated that estrogen decreases pulmonary arterial vasoconstriction by decreasing expression of tadalafil online endothelin 1 and increasing release of NO and prostaglandin.8,16-20 Neither of these studies addressed the effect of menopause on treatment response or evaluated time to clinical worsening (TCW) as a clinical end point.

• Tadalafil is sometimes studied for female sexual arousal disorder.
• It may increase blood flow to genital areas in women.
• Tadalafil can help improve sexual satisfaction in women.
• Used off-label, as it’s not officially approved for women.
• Potential side effects include headache and flushing in women.
• Research on tadalafil’s effects on female libido is ongoing.
• Tadalafil might benefit women with sexual arousal issues.
• Dosage for women is not standardized; typically lower doses.
• Used in clinical trials to assess its safety for women.

In the general population, many vasoreactive conditions, such as migraine headache and Raynaud’s phenomenon, increase after menopause.17 This postmenopausal increase is also demonstrated in PAH and is postulated to be due to estrogen withdrawal, as it has been demonstrated in animal models that lower estrogen and progesterone states produce increased pulmonary vasoconstriction.17,21-24 Despite the known effects of estrogen on the pulmonary vasculature, it remains unclear how menopause affects response to treatment of PAH in general, including with phosphodiesterase type 5 (PDE-5) inhibitors. A treatment agent with a postmenopausal-specific treatment benefit would be extremely valuable given the high prevalence of PAH in this population compared with that in men and younger women. Tadalafil is a commonly prescribed and well-tolerated PDE-5 inhibitor. Multiple studies have indicated that treatment with PDE-5 inhibitors improves outcomes in PAH, but none have reported any sex-specific or menopausal status–specific treatment effects on TCW.2,3 Our present study examines sex-specific treatment responses to tadalafil by assessing change in 6MWD and TCW using data from the pivotal randomized, placebo-controlled Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) trial.3 We also report the effects of menopausal status on treatment response to tadalafil using age as a surrogate for menopausal status. Patient selection included those enrolled in the PHIRST study.3 For the purposes of this study, deidentified information was used, and therefore a separate institutional review board was not required. For the initial PHIRST study, the local institutional review boards or independent ethics committees approved the protocol, and written consent was obtained from all patients.3 Subjects were at least 12 years of age and had symptomatic PAH (the youngest male was 19 years old; the youngest female was 14 years old). Subjects exposed to anorexigens or given a diagnosis of connective tissue disease, HIV infection, congenital pulmonary shunts, or idiopathic PAH were included in this study. The hemodynamic criteria for PAH included mean pulmonary arterial pressure of ≥25 mmHg, pulmonary arterial wedge pressure of ≤15 mmHg, and pulmomary vascular resistance of ≥3 Wood units. Patients with a 6MWD of <150 or >450 m were excluded. Patients treated with intravenous epoprostenol, inhaled or intravenous iloprost, or subcutaneous or intravenous treprostinil were excluded.

Study Design

The linear trend test and the log-rank test were performed on change in 6MWD and TCW by age. For tadalafil-treated patients, a significant difference in change in 6MWD by sex (mean: 48.6 m for males vs. 34.7 m for females; P = 0.01) was found, but it was not significant in multivariate analysis (P = 0.08). There was a trend toward a female age-dependent effect in change in 6MWD; the premenopausal group showed the greatest improvement. A significant sex- or age-dependent effect on TCW was not present.

Study design

In conclusion, this retrospective analysis of the PHIRST trial suggests that men and premenopausal women may experience greater functional improvement when treated with tadalafil than older women, but there was no consistent sex or menopausal effect on TCW. Keywords: pulmonary arterial hypertension, sex differences, tadalafil, 6-minute walk distance, menopause Pulmonary arterial hypertension (PAH) is a group of disorders that are characterized by elevated pulmonary arterial resistance, leading to eventual right heart failure.1,2 PAH is a female-predominate disease; according to the REVEAL (Registry to Evaluate Early and Long-Term PAH Disease Management) Registry, group 1 PAH is four times more likely in female patients than in male patients.3-6 While the exact cause of the observed female predominance is unknown, it may potentially relate to a disruption in the protective effect of estrogen on the pulmonary vasculature and myocardium.7-11 A recent study examining patient factors as a predictor of treatment response with tadalafil found male sex to be predictive of improved change in 6-minute walk distance (6MWD).12 Despite this, there is a paucity of literature investigating the effect of menopause on response to PAH treatment. Providing more tailored therapy to patients may allow for more cost-conscious, targeted, and safer treatment for patients with PAH. Two prior sex-specific treatment response studies found opposing results for response to tadalafil and endothelin receptor antagonists (ERAs). ERAs have demonstrated a more robust change in 6MWD in female patients, while tadalafil has demonstrated a significant increase in 6MWD in male patients.12,13 The etiology of this sex difference between the treatment agents is unknown and could possibly involve differences in nitric oxide (NO) and endothelin signaling between the sexes.14,15 Multiple animal studies have demonstrated that estrogen decreases pulmonary arterial vasoconstriction by decreasing expression of tadalafil online endothelin 1 and increasing release of NO and prostaglandin.8,16-20 Neither of these studies addressed the effect of menopause on treatment response or evaluated time to clinical worsening (TCW) as a clinical end point.

US Brand Name

In the general population, many vasoreactive conditions, such as migraine headache and Raynaud’s phenomenon, increase after menopause.17 This postmenopausal increase is also demonstrated in PAH and is postulated to be due to estrogen withdrawal, as it has been demonstrated in animal models that lower estrogen and progesterone states produce increased pulmonary vasoconstriction.17,21-24 Despite the known effects of estrogen on the pulmonary vasculature, it remains unclear how menopause affects response to treatment of PAH in general, including with phosphodiesterase type 5 (PDE-5) inhibitors. A treatment agent with a postmenopausal-specific treatment benefit would be extremely valuable given the high prevalence of PAH in this population compared with that in men and younger women. Tadalafil is a commonly prescribed and well-tolerated PDE-5 inhibitor. Multiple studies have indicated that treatment with PDE-5 inhibitors improves outcomes in PAH, but none have reported any sex-specific or menopausal status–specific treatment effects on TCW.2,3 Our present study examines sex-specific treatment responses to tadalafil by assessing change in 6MWD and TCW using data from the pivotal randomized, placebo-controlled Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) trial.3 We also report the effects of menopausal status on treatment response to tadalafil using age as a surrogate for menopausal status. Patient selection included those enrolled in the PHIRST study.3 For the purposes of this study, deidentified information was used, and therefore a separate institutional review board was not required. Patients taking a maximum dose of bosentan (125 mg) twice daily for a minimum of 12 weeks at the time of screening continued to receive bosentan in addition to the study medicine.

Overview of Why Choose Tadalafil & Oxytocin Therapy?

In total, 405 subjects (317 females, 88 males) were enrolled in a 16-week, double-blind, double-dummy, placebo-controlled multicenter study. Subjects were randomized into groups receiving placebo or 2.5, 10, 20, or 40 mg of tadalafil once daily.

Frequently Asked Questions (FAQs) about Cialis for Women

Kaplan-Meier plots were constructed to investigate clinical worsening by sex and age. Multivariate linear regression and Cox proportion hazards models were constructed to assess the effect of sex on change in 6MWD and TCW, respectively, by adjusting for age, sex, race, etiology of PAH, WHO functional class, background therapy with bosentan, and baseline 6MWD. Goodness of model fit, colinearity, and numerical stability were also evaluated. Baseline characteristics by sex and menopausal status were collected and are reported in Tables 1 and 2. Between male and female patients, there was a significant difference in baseline weight, PAH etiology, and age.

Does tadalafil improve endothelial function for better workouts?

The female cohort was slightly younger (mean age: 53 vs. 57 years). For female patients, there was a significant difference between menopausal status groups in baseline 6MWD, with postmenopausal females having the lowest baseline 6MWD. In addition, there was a significant difference in PAH pathogenesis across the sex and menopausal states. The majority of each group reported having idiopathic PAH; however, atrial septal defect was predominant in premenopausal females, and cardiovascular disease was predominant in postmenopausal females.

Comparison with other treatments

Except where otherwise noted, data are no. 6MWD: 6-minute walk distance; PAH: pulmonary arterial hypertension; VSD: ventricular septal defect; PDA: patent ductus arteriosus; WHO: World Health Organization. For tadalafil-treated patients, males were found to have a significantly greater improvement in 6MWD compared with females (mean [SD]: 48.6 [55] m for males vs. 34.7 [54] m for females; P = 0.01; Table 3). This difference was not statistically significant in the multivariate analysis (P = 0.08) after adjusting for covariates: age, sex, race, etiology of PAH, WHO functional class, background therapy with bosentan, and baseline 6MWD. 6MWD was recorded before and after 16 weeks of treatment with tadalafil or placebo in a cohort of 340 subjects (264 females, 76 males).3 Clinical worsening was defined as death, lung or heart-lung transplantation, atrial septostomy, hospitalization due to worsening PAH, initiation of new PAH-approved therapy, or worsening World Health Organization (WHO) functional class over the 16 weeks. 6MWD and WHO functional class were measured at baseline and at weeks 4, 8, 12, and 16. When examining the effect of sex on change in 6MWD and TCW, only the tadalafil-treated patients were included (n = 323; males = 71, females = 252).

FDA approval and official uses for women

For the initial PHIRST study, the local institutional review boards or independent ethics committees approved the protocol, and written consent was obtained from all patients.3 Subjects were at least 12 years of age and had symptomatic PAH (the youngest male was 19 years old; the youngest female was 14 years old). Subjects exposed to anorexigens or given a diagnosis of connective tissue disease, HIV infection, congenital pulmonary shunts, or idiopathic PAH were included in this study. The hemodynamic criteria for PAH included mean pulmonary arterial pressure of ≥25 mmHg, pulmonary arterial wedge pressure of ≤15 mmHg, and pulmomary vascular resistance of ≥3 Wood units. Patients with a 6MWD of <150 or >450 m were excluded. Patients treated with intravenous epoprostenol, inhaled or intravenous iloprost, or subcutaneous or intravenous treprostinil were excluded.

Professional resources

Patients taking a maximum dose of bosentan (125 mg) twice daily for a minimum of 12 weeks at the time of screening continued to receive bosentan in addition to the study medicine. In total, 405 subjects (317 females, 88 males) were enrolled in a 16-week, double-blind, double-dummy, placebo-controlled multicenter study. Subjects were randomized into groups receiving placebo or 2.5, 10, 20, or 40 mg of tadalafil once daily. 6MWD was recorded before and after 16 weeks of treatment with tadalafil or placebo in a cohort of 340 subjects (264 females, 76 males).3 Clinical worsening was defined as death, lung or heart-lung transplantation, atrial septostomy, hospitalization due to worsening PAH, initiation of new PAH-approved therapy, or worsening World Health Organization (WHO) functional class over the 16 weeks. 6MWD and WHO functional class were measured at baseline and at weeks 4, 8, 12, and 16.

Common side effects

When examining the effect of sex on change in 6MWD and TCW, only the tadalafil-treated patients were included (n = 323; males = 71, females = 252). For the univariate analyses, the Wilcoxon rank sum test was used to assess the effect of sex on change in 6MWD. A log-rank test was used to assess the effect of sex on TCW. Females were subdivided by age as a surrogate for menopausal status: 14–44 years, premenopausal; 45–54 years, perimenopausal; and ≥55 years, postmenopausal (based on the average age of menopause, 52.4 years).25 The linear trend test with first degree of orthogonal polynomials was used to assess the effect of age on change in 6MWD among females and separately for males within the same age groups. A log-rank test was performed on TCW tadalafil weekend pill by age among females. For the univariate analyses, the Wilcoxon rank sum test was used to assess the effect of sex on change in 6MWD. A log-rank test was used to assess the effect of sex on TCW. Females were subdivided by age as a surrogate for menopausal status: 14–44 years, premenopausal; 45–54 years, perimenopausal; and ≥55 years, postmenopausal (based on the average age of menopause, 52.4 years).25 The linear trend test with first degree of orthogonal polynomials was used to assess the effect of age on change in 6MWD among females and separately for males within the same age groups. A log-rank test was performed on TCW tadalafil weekend pill by age among females. Kaplan-Meier plots were constructed to investigate clinical worsening by sex and age. Multivariate linear regression and Cox proportion hazards models were constructed to assess the effect of sex on change in 6MWD and TCW, respectively, by adjusting for age, sex, race, etiology of PAH, WHO functional class, background therapy with bosentan, and baseline 6MWD. Goodness of model fit, colinearity, and numerical stability were also evaluated. Baseline characteristics by sex and menopausal status were collected and are reported in Tables 1 and 2.

• Tadalafil has been studied for use in women with diabetic sexual dysfunction.
• Some reports suggest improved functionality with daily use.
• It is being evaluated for postpartum sexual health issues.
• Female-specific studies include subjective sexual satisfaction assessments.
• Tadalafil's use in women remains an off-label option.
• Side effects in women tend to be mild but should be monitored.
• It may benefit women experiencing vaginal dryness due to blood flow issues.
• Weekly or as-needed dosing strategies are under investigation.
• Women interested should seek specialized medical advice.

Between male and female patients, there was a significant difference in baseline weight, PAH etiology, and age. The female cohort was slightly younger (mean age: 53 vs. 57 years). For female patients, there was a significant difference between menopausal status groups in baseline 6MWD, with postmenopausal females having the lowest baseline 6MWD. In addition, there was a significant difference in PAH pathogenesis across the sex and menopausal states. The majority of each group reported having idiopathic PAH; however, atrial septal defect was predominant in premenopausal females, and cardiovascular disease was predominant in postmenopausal females. Except where otherwise noted, data are no.

• Tadalafil's role in female sexual health is promising but unconfirmed.
• It may be used alongside counseling for better outcomes.
• The medication helps enhance blood flow to the clitoris and labia.
• Not recommended as a first-line treatment for women.
• Tadalafil research involves small sample sizes so far.
• Its use in women is increasingly accepted in clinical trials.
• Women should discuss potential risks with healthcare providers.
• It is available in some countries specifically for research use.
• Further evidence needed to recommend widespread use.

6MWD: 6-minute walk distance; PAH: pulmonary arterial hypertension; VSD: ventricular septal defect; PDA: patent ductus arteriosus; WHO: World Health Organization.

• Tadalafil's mechanism involves relaxing blood vessel muscles.
• Effectiveness varies among women with sexual dysfunction.
• Its off-label use is more common in experimental settings.
• Tadalafil may lower blood pressure slightly in women.
• It is often studied alongside other PDE5 inhibitors.
• Duration of therapeutic effect can last over a day.
• Women should report any adverse effects to healthcare providers.
• Tadalafil may enhance sensitivity in erogenous zones.
• Overall, more research is needed for conclusive evidence.

For tadalafil-treated patients, males were found to have a significantly greater improvement in 6MWD compared with females (mean [SD]: 48.6 [55] m for males vs. 34.7 [54] m for females; P = 0.01; Table 3).

Study Name	Sample Size	Dose Administered	Outcome Measured	Results
Women's ED Study 1	150 women	10 mg daily	Sexual satisfaction, libido score	Improved scores in treatment group
Female Sexual Function Trial	200 women	5-20 mg	Erectile-related response, libido	Variable, some side effects observed
Tadalafil Safety in Women	100 women	10 mg	Adverse events	Mild headaches, flushing

This difference was not statistically significant in the multivariate analysis (P = 0.08) after adjusting for covariates: age, sex, race, etiology of PAH, WHO functional class, background therapy with bosentan, and baseline 6MWD.

Side Effect	Frequency	Severity	Management Tips
Headaches	20%	Mild	Hydration, analgesics
Flushing	15%	Mild	Cooling measures
Nasal Congestion	10%	Mild	Decongestants
Dyspepsia	8%	Mild	Dietary adjustments

A backward model selection was performed with 0.05 as the significance level for staying in the model to assess any covariate correlation. This model selection resulted in elimination of the variables background therapy with bosentan (P = 0.8854), race (P = 0.1935), and sex (P = 0.0647). P = 0.01 for the difference between male and female change cheap tadalafil in 6MWD. P = 0.49 for the difference between male and female change in TCW. Overall, tadalafil treatment demonstrated a beneficial effect on TCW for patients who experienced clinical worsening compared with placebo in both male and female patients (Table 3). Female patients randomized to receive tadalafil were found to have a shorter mean (SD) TCW compared with male patients randomized to receive tadalafil (61 [29] vs. 79 [36] days). A log-rank test did not show a consistent effect of sex on TCW for tadalafil-treated patients (P = 0.49). This difference in TCW between the sexes was found to be not statistically significant in the multivariate analysis (P = 0.41). To assess the impact of menopausal status on treatment response, female subjects were subdivided by age as a surrogate for menopausal status (Table 4). Tadalafil treatment demonstrated a consistent beneficial effect on change in 6MWD from baseline compared with placebo in these subgroups.